

## **Idecabtagene Vicleucel Market**

Market Report | 2025-05-01 | 278 pages | Datastring Consulting

### **AVAILABLE LICENSES:**

- Multi User License \$4200.00

### **Report description:**

#### Description

The market, for Idecabtagene vicleucel was estimated at \$1.7 billion in 2024; and it is anticipated to increase to \$4.8 billion by 2030 with projections indicating a growth to around \$11.2 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 18.8% over the forecast period.

#### Segmentation

To see report segmentation please view the table of contents, or ask us for samples.

### **Table of Contents:**

Chapter 1: Executive Summary - Major Markets & Their Performance - Statistical Snapshots

Chapter 2: Research Methodology

2.1: Axioms & Postulates

2.2: Market Introduction & Research Methodology - Estimation & Forecast Parameters / Major Databases & Sources

Chapter 3: Market Dynamics

3.1: Market Overview - Drivers / Restraints / Opportunities / M4 Factors

3.2: Market Trends

3.2.1: Introduction & Narratives

3.2.2: Market Trends - Impact Analysis (Short, Medium & Long Term Impacts)

3.3: Supply Chain Analysis

3.4: Porter's Five Forces - Suppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry

Chapter 4: Global Idecabtagene Vicleucel Market Size, Opportunities & Strategic Insights, by Patient Demographics

4.1: Pediatrics

4.2: Adults

4.3: Elderly

Chapter 5: Global Idecabtagene Vicleucel Market Size, Opportunities & Strategic Insights, by Therapeutic Applications

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 5.1: Oncology
- 5.2: Hematology
- 5.3: Cellular Therapy
- 5.4: Others

Chapter 6: Global Idecabtagene Vicleucel Market Size, Opportunities & Strategic Insights, by Treatment Path

- 6.1: First-line Therapy
- 6.2: Second-line Therapy
- 6.3: Palliative Care

Chapter 7: Global Idecabtagene Vicleucel Market Size, Opportunities & Strategic Insights, by Healthcare Facilities

- 7.1: Hospitals
- 7.2: Speciality Clinics
- 7.3: Research Laboratories

Chapter 8: Global Idecabtagene Vicleucel Market Size, Opportunities & Strategic Insights, by Drug Distribution Channels

- 8.1: Retail Pharmacies
- 8.2: Hospital Pharmacies
- 8.3: Online Pharmacies

Chapter 9: Idecabtagene Vicleucel Market, by Region

9.1: North America Idecabtagene Vicleucel Market Size, Opportunities, Key Trends & Strategic Insights

- 9.1.1: U.S.
- 9.1.2: Canada

9.2: Europe Idecabtagene Vicleucel Market Size, Opportunities, Key Trends & Strategic Insights

- 9.2.1: Germany
- 9.2.2: France
- 9.2.3: UK
- 9.2.4: Italy
- 9.2.5: The Netherlands
- 9.2.6: Rest of EU

9.3: Asia Pacific Idecabtagene Vicleucel Market Size, Opportunities, Key Trends & Strategic Insights

- 9.3.1: China
- 9.3.2: Japan
- 9.3.3: South Korea
- 9.3.4: India
- 9.3.5: Australia
- 9.3.6: Thailand
- 9.3.7: Rest of APAC

9.4: Middle East & Africa Idecabtagene Vicleucel Market Size, Opportunities, Key Trends & Strategic Insights

- 9.4.1: Saudi Arabia
- 9.4.2: United Arab Emirates
- 9.4.3: South Africa
- 9.4.4: Rest of MEA

9.5: Latin America Idecabtagene Vicleucel Market Size, Opportunities, Key Trends & Strategic Insights

- 9.5.1: Brazil
- 9.5.2: Mexico
- 9.5.3: Rest of LA

9.6: CIS Idecabtagene Vicleucel Market Size, Opportunities, Key Trends & Strategic Insights

- 9.6.1: Russia
- 9.6.2: Rest of CIS

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Chapter 10: Competitive Landscape

### 10.1: Competitive Dashboard & Market Share Analysis

### 10.2: Company Profiles (Overview, Financials, Developments, SWOT)

10.2.1: Bluebird Bio

10.2.2: Bristol Myers Squibb

10.2.3: Janssen Biotech

10.2.4: Novartis

10.2.5: Gilead Sciences

10.2.6: Kite Pharma

10.2.7: Celgene Corporation

10.2.8: Juno Therapeutics

10.2.9: Fate Therapeutics

10.2.10: Atara Biotherapeutics

10.2.11: Allogene Therapeutics

10.2.12: Amgen.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Idecabtagene Vicleucel Market**

Market Report | 2025-05-01 | 278 pages | Datastring Consulting

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Multi User License	\$4200.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com